Stockwinners Market Radar for August 15, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:50 EDT LeMaitre CEO sells $3.2M in common stock - In a regulatory filing, LeMaitre disclosed that its CEO George Lemaitre sold 58.6K shares of common stock on August 11th in a total transaction size of $3.2M.

19:39 EDT Electronic Arts board authorizes new program to repurchase up to $2.6B in shares - In a regulatory filing, Electronic Arts disclosed that on August 11, the company's board authorized a new program to repurchase up to $2.6B of the company's common stock. "Repurchases under this new share repurchase authorization will begin upon the completion of repurchases under the company's current share repurchase authorization, which is expected in late September or early October 2022. This new stock repurchase program expires on November 4, 2024," the company stated.

17:58 EDT Greenlight Capital buys Rivian, exits Intel in Q2 - David Einhorn's Greenlight Capital disclosed in an SEC filing its holdings as of June 30, 2022. The fund's four new buys during the second quarter included, by size of position, Concentrix (CNXC) and Rivian (RIVN). Greenlight exited nine positions during the quarter, including by size of previous position TD Synnex (SNX), Intel (INTC), Gulfport Energy (GPOR), Playstudios (MYPS), and First Trust Natural Gas ETF (FCG). The fund increased its stake in 11 holdings, including by size of previous position Consol Energy (CEIX), Kyndryl Holdings (KD), SPDR Gold Shares (GLD), Atlas Air (AAWW), and Capri Holdings (CPRI). Greenlight reduced its stake in seven holdings, including by size of previous position Teck Resources (TECK), Change Healthcare (CHNG), Chemours (CC), Brighthouse Financial (BHF), and International Seaways (INSW). The fund's top holdings as of June 30, in order of size, were Green Brick (GRBK), Brighthouse, Atlas Air, Consol Energy, and Teck.

17:25 EDT Third Point adds Disney, exits Intuit in Q2 - Third Point disclosed in an SEC filing its holdings as of June 30, 2022. The fund's four new buys during the second quarter included, by size of position, Colgate-Palmolive (CL), Antero Resources (AR), Disney (DIS), and T-Mobile (TMUS). Third Point exited 21 holdings during the quarter, including by size of previous position S&P Global (SPGI), Intuit (INTU), Avantor (AVTR), Iqvia (IQV), and Zendesk (ZEN). The fund increased its stake in four holdings, including by size of previous position Ovintiv (OVV), Cenovus Energy (CVE), and Sema4 Holdings (SMFR). Third Point reduced its stake in 14 holdings, including by size of previous position SentinelOne (S), PG&E (PCG), Danaher (DHR), CSX (CSX), and DuPont (DD). The fund's top holdings as of June 30, in order of size, were PG&E, Danaher, UnitedHealth (UNH), Ovintiv, and EQT (EQT).

17:16 EDT Paulson buys VMware, exits DiDi in Q2 - John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of June 30, 2022. The fund's five new buys during the second quarter included, by size of position, VMware (VMW) and IronSource (IS). Paulson exited six positions during the quarter, including by size of previous position SPDR Gold Shares (GLD), DiDi (DIDIY), Exxon Mobil (XOM), VanEck Oil Services ETF (OIH), and TIM SA (TIMB). The fund increased its stake in two holdings, namely Horizon Therapeutics (HZNP) and Bausch Health (BHC). Paulson reduced its stake in four holdings, including by size of previous position Endo (ENDP), Occidental (OXY), Pacira Biosciences (PCRX) and Newmark (NMRK). The fund's top holdings as of June 30, in order of size, were Horizon Therapeutics, Bausch Health, BrightSphere (BSIG), Occidental, and KraneShares CSI China Internet ETF (KWEB).

17:01 EDT Impel Pharmaceuticals expects cash to fund operations into 2024 - As of June 30, 2022, Impel had approximately $97.8 million in cash and cash equivalents. The Company projects, based on its current operating plan, it has sufficient capital to fund operations into 2024.

16:50 EDT Vimeo reports July revenue up 10% - Vimeo reports July monthly metrics, with revenue up 10% and Average Revenue Per User up 7% y/y. Reference Link

16:46 EDT iSun says expects to continue to accelerate revenue growth - The company states: "iSun's investments perfectly positions us to respond to the increase in energy demand associated with automotive electrification, and make iSun an indispensable partner to consumers, businesses, industries, and utilities as they transition to renewable energy sources. With the recent climate legislation, we anticipate a more favorable environment for solar development and EV infrastructure. Our breadth of capabilities and depth of services position us to continue our growth trajectory. We now have a platform that can deliver a full suite of services. We have assembled a team that has the experience and expertise to execute on our capabilities. We have tremendous demand, and a growing customer base. We are confident that these conditions will continue to accelerate our established year-over-year revenue growth."

16:44 EDT Verb Technology reports R&D expenses down 57% due to cost reductions plan - Q2 Research and development expenses were $1.4M, as compared to $3.2M for the same period last year, reflecting a 57% decrease due to planned cost reductions. R&D expenses were down 13% over the Q1.

16:39 EDT Dentsply Sirona receives noncompliance notice from Nasdaq - Dentsply Sirona announced that, as expected, it received written notification from Nasdaq that the company remains out of compliance with the Nasdaq listing rules because the company has not yet filed its quarterly reports on Form 10-Q for the periods ended March 31 and June 30. Nasdaq Listing Rule 5250 requires Nasdaq-listed companies to timely file all periodic reports.

16:35 EDT Edenbrook Capital sends letter to Hemisphere Media special committee - Edenbrook Capital, LLC, one of the largest public shareholders of Hemisphere Media Group, Inc., with ownership of approximately 14.94% of the publicly traded A shares and 7.65% of the total company, including the privately held, super-voting B shares, announced that it has delivered a letter to the Members of the Special Committee of the Board of Directors of Hemisphere. The letter says in part: "In this letter we aim to demonstrate multiple troubling examples of how Searchlight appears to have abused its position as insider owners of Hemisphere and, by extension, how we believe the Special Committee abrogated its fiduciary duty to public shareholders by allowing Searchlight to run roughshod over the process in a way that favored Searchlight at the expense of public shareholders... In short, had the Company sold Pantaya to a willing bidder for $200 million, we believe public shareholders would have a remaining public company valued as an ongoing tradeable company at prices 73-167% above the $7.00 per share transaction price proposed by the Insider Takeover. We believe that you have allowed, and continue to allow, Searchlight to escape with a lower price for Pantaya and for the Company as a whole, when public shareholders would be better off selling Pantaya to an unconflicted outside buyer and maintaining ownership in the remaining valuable, cash-generative assets. Why not just start over and pursue selling Pantaya along with the entire Company to an unconflicted outside buyer? In any case, your continued recommendation that public shareholders support a $7.00 bid from a conflicted insider that dramatically undervalues the company is, in our view, an outrageous dereliction of your fiduciary duties to all shareholders."

16:33 EDT Lone Pine buys Booking, exits Snap in Q2 - Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of June 30, 2022. The fund's eight new buys during the second quarter included, by size of position, LPL Financial (LPLA), Booking (BKNG), Alphabet Class A (GOOGL), Epam Systems (EPAM), and PayPal (PYPL). Lone Pine exited eight positions during the quarter, including by size of previous position Snap (SNAP), DoorDash (DASH), Datadog (DDOG), Victoria's Secret (VSCO), and Bill.com (BILL). The fund increased its stake in seven holdings, including by size of previous position Thermo Fisher (TMO), Dick's Sporting Goods (DKS), Meta (META), TSMC (TSM), and Atlassian (TEAM). Lone Pine reduced its stake in eight holdings, including by size of previous position Shopify (SHOP), Microsoft (MSFT), Workday (WDAY), ServiceNow (NOW), and Block (SQ). The fund's top holdings as of June 30, in order of size, were Amazon (AMZN), Microsoft, Meta, TSMC, and Workday.

16:27 EDT Walmart adds Paramount+ Essential subscription at no cost for Walmart+ members - Walmart (WMT) announced it is adding a new streaming benefit, as Walmart+ will soon be available for members with a Paramount+ Essential subscription at no extra cost. Walmart+ members will be able to stream premium entertainment as a benefit for the first time as part of their membership starting in September, the company confirmed in a press release. "Paramount has enjoyed a close relationship with Walmart for years, and Walmart customers connect with Paramount's beloved brands, content, and characters every day through a range of consumer products available throughout Walmart stores," said Jeff Shultz, chief strategy officer and chief business development officer, Paramount Streaming (PARA). "Now, pairing Walmart's expansive reach across the country with Paramount+'s broad and popular content that offers something for everyone is a unique opportunity to expand our partnership. Together we will bring Walmart+ members the full breadth of Paramount+ programming."

16:23 EDT Berkshire Hathaway exits Verizon position

16:22 EDT David Tepper's Appaloosa buys Salesforce, exits Nordstrom in Q2 - David Tepper's Appaloosa Management disclosed in an SEC filings its holdings as of June 30, 2022. The fund's eight new buys during the second quarter included, by size of postiion, Constellation Energy (CEG), Salesforce (CRM), Aptiv (APTV), HCA Healthcare (HCA), and Alibaba (BABA). Appaloosa exited 11 positions during the quarter, including by size of previous position Energy Select Sector SPDR Fund (XLE), Goodyear Tire (GT), SPDR S&P Oil & Gas Exploration & Production ETF (XOP), Freeport-McMoRan (FCX), and Nordstrom (JWN). The fund increased its stake in four holdings, including by size of previous position Kohl's (KSS), MPLX (MPLX), Energy Transfer (ET), and Meta (META). Appaloosa reduced its stake in 16 holdings, including by size of previous position Micron (MU), Amazon (AMZN), Alphabet Class C (GOOG), Occidental (OXY), and Macy's (M). The fund's top holdings as of June 30, in order of size, were Alphabet Class C, Meta, Amazon, Constellation Energy, and Macy's.

16:21 EDT Polished sees low double-digit FY22 sales growth - The company states that it "now expects low double-digit net sales growth in fiscal year 2022. Updated guidance reflects the expected impact of continued supply chain disruptions, material increases in transportation costs and significant inflation. The company expects to provide additional fiscal year guidance once its financial statements have been finalized. The Company's performance remains strong, and it continues to expect profitable growth through the remainder of fiscal year 2022 and beyond."

16:20 EDT Albireo Pharma sees sufficient cash, equivalents into 2024 - The company had cash and cash equivalents of $181.0 million as of June 30, 2022, versus $216.7 million as of March 31, 2022. The company expects to have sufficient cash into 2024 based on current revenue and expense projections. Bylvay 2022 sales are now expected to be $24 million.

16:17 EDT Alkuri Global Acquisition Corp trading resumes

16:12 EDT ICF International awarded IDIQ contract with ceiling value of $320M - The National Institutes of Health National Cancer Institute's Division of Cancer Epidemiology and Genetics recently selected ICF as one of five awardees for a new multiple-award indefinite delivery, indefinite quantity contract to provide epidemiologic and clinical operations support for studies and other research activities. The IDIQ, which was awarded in the second quarter of 2022, has a ceiling value of $320M across all awardees and term of 10 years, including a five-year base and a five-year option period.

16:09 EDT AIM ImmunoTech provides update on Jorgl Activist Group Litigation - AIM ImmunoTech issued the following statement regarding the outcome of a hearing in the Delaware Court of Chancery concerning a motion for a temporary restraining order sought by activist shareholder Jonathan Jorgl: "This morning we announced in a Form 10-Q filing that on August 12, 2022, a hearing was held in the Delaware Court of Chancery concerning a motion for a temporary restraining order sought by Mr. Jorgl related to his nomination of director candidates for election to the Board at our 2022 Annual Meeting of Stockholders. The Court of Chancery reconvened the hearing today and denied Mr. Jorgl's motion for a TRO. The Court scheduled a hearing on Mr. Jorgl's motion for a preliminary injunction to be held on October 5, 2022. We will continue to take steps to protect the rights of all shareholders and will provide further updates as available."

16:08 EDT INVO Bioscience anticipates Q3 revenue to grow significantly from Q2 - Steve Shum, CEO of INVO, commented, "In our existing clinics, we continue to see growing volume in patient inquiries and consultations, a leading indicator of future IVC cycles. Based on current cycle expectations, we are anticipating Q3 clinic revenue to increase significantly compared to our Q2 results. We are actively working within our U.S. distribution business and with international partners to enhance end-market awareness and to obtain necessary regulatory approval in key markets, such as China. On the acquisition front, we are excited by the prospect of bringing one or more established and profitable fertility centers into our operations," Shum expanded. "The practitioners we are in discussion with share our vision of leveraging the INVOcell solution to expand access to fertility and agree with our position that IVF and IVC are complementary to one another."

16:07 EDT Qiagen launches syndromic test for QIAstat-Dx device to combat Monkeypox - QIAGEN announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel - currently for research use only, RUO - comes in cartridge form to run on QIAGEN's QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus, herpes simplex virus 1, HSV2, human herpesvirus 6, varicella-zoster virus and enterovirus - pathogens that all produce similar-looking vesicular lesions. "Monkeypox cases are soaring across the globe with many demographic groups infected. Surveillance is an essential tool in the fight against infectious diseases. QIAstat-Dx Viral Vesicular Panel in combination with the QIAstat-Dx platform will allow medical researchers to detect monkeypox with gold-standard PCR testing-technology in about one hour," said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN. "Currently the world's only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe."

16:05 EDT Equillium expects cash to fund operations for the next 12 months - Cash, cash equivalents and short-term investments totaled $57.6 million as of June 30, 2022, compared to $68.8 million as of March 31, 2022. Equillium believes that its cash and investments, together with its existing and available committed equity line, are sufficient to fund its operations for at least the next 12 months.

15:57 EDT eBay launches first collection of Funko products - eBay announced the launch of a series of exclusive Funko products as part of a newly formed collaboration with Funko, a "leading pop culture and lifestyle brand." Through this collaboration, eBay combines its global reach and unique inventory to continue to bring a seamless experience that allows enthusiasts to access high passion and high value items, including exclusive-to-eBay Funko products.

15:30 EDT Tonix discusses preclinical smallpox/monkeypox vaccine candidate in presentation - Tonix Pharmaceuticals stated in presentation slides that TNX-801, a cloned version of horsepox, without any insert, purified from cell culture, is preclinical, pre-IND and being developed for market entry as a potential smallpox and monkeypox vaccine. Reference Link

15:01 EDT CynergisTek renews several contract extensions valued at over $300,000 - CynergisTek announces a well-known medical device manufacturer is renewing multiple Data Privacy and Compliance contract extensions worth over $300,000. The globally recognized organization is extending its seven-year relationship with CynergisTek into 2023 to support its operations in 150 countries. CynergisTek is providing its long-standing client with robust Data Privacy Program Support services to assist in ongoing compliance efforts, data protection, and risk advisory services. Through the Privacy program, CynergisTek's subject matter experts support data privacy-related projects to better manage risk and enhance compliance. Clients receive strategic guidance and tailored roadmaps to meet regulatory requirements and implement procedures to maintain a high level of compliance.

14:52 EDT Tiger Global buys Alphabet Class A, exits Zoom Video in Q2 - Chase Coleman's Tiger Global disclosed in an SEC filing its holdings as of June 30, 2022. The fund's four new buys during the second quarter included, by size of position, Alphabet Class A (GOOGL), Samsara (IOT), Lamb Weston (LW), and Zillow Class C (Z). Tiger exited 19 positions during the quarter, included by size of previous position DocuSign (DOCU), Elastic (ESTC), Zoom Video (ZM), IronSource (IS), and Perimeter Solutions (PRM). The fund increased its stake in eight holdings, including by size of previous position Kanzhun (BZ), Gitlab (GTLB), SentinelOne (S), HashiCorp (HCP), and Olo Class A (OLO). Tiger reduced its stake in 48 holdings, including by size of previous position Snowflake (SNOW), Nu Holdings (NU), Sea Ltd. (SE), Carvana (CVNA), and Microsoft (MSFT). The fund's top holdings as of June 30, in order of size, were JD.com (JD), Microsoft, Crowdstrike (CRWD), Nu Holdings, and Meta Platforms (META).

14:32 EDT Choice Hotels appoints Noha Abdalla as Chief Marketing Officer - Choice Hotels International has appointed Noha Abdalla to the role of chief marketing officer, reporting directly to President and CEO Patrick Pacious. Abdalla joins Choice Hotels from MyEyeDr., a Goldman Sachs-equity backed optical company, where she served as chief marketing officer. Pacious said: "Noha is an experienced leader with a successful track record of taking world-class brands to the next level. As the company continues to add new experiences and offerings for travelers, we're confident she is the best person to keep Choice's finger on the pulse of evolving consumer preferences while driving loyalty and innovation to support our diverse portfolio of brands."

14:15 EDT Pembina Pipeline completes transaction with KKR to create PGI - Pembina Pipeline (PBA) announces that it has completed its previously announced joint venture transaction with KKR (KKR) to combine their respective western Canadian natural gas processing assets into a single, new joint venture entity, Pembina Gas Infrastructure Inc., or "PGI." Scott Burrows, Pembina's President and CEO, said: "We are excited to officially announce the creation of PGI, a premier gas processing entity in Western Canada that will provide incredible value for Pembina, our partner KKR, and our customers. Pembina has enjoyed a strong relationship with KKR at Veresen Midstream over the past four years and the creation of PGI is a natural next step that will unlock growth and provide increased service offerings to customers throughout the Montney and Duverney formations, from central Alberta to northeast British Columbia."

13:58 EDT Alkuri Global Acquisition Corp trading halted, news pending

13:28 EDT Disney says it 'welcomes the views' of investors after Third Point letter - The Walt Disney Company issued the following statement: "We welcome the views of all our investors. As our third quarter results demonstrate, The Walt Disney Company continues to deliver strong financial results powered by world-class storytelling and our unique and highly valuable content creation and distribution ecosystem. Under the leadership of Bob Chapek, the company has delivered this strong performance while navigating the COVID-19 pandemic and its aftermath, including record streaming subscriptions and the reopening of our parks, where we have seen strong revenue and profit growth in our domestic parks business. Our independent and experienced Board has significant expertise in branded, consumer-facing and technology businesses as well as talent-driven enterprises. The Board has also benefited from continuous refreshment with an average tenure of four years."

13:09 EDT Delta Air Lines resumes nonstop service from LAX to Haneda - Delta will resume flights from Los Angeles International Airport to Tokyo International Airport beginning Oct. 30 in anticipation of Japan's easing travel restrictions The route will start operating three times weekly before moving to daily starting Dec. 1. The restart of service will use Airbus 330-900neo aircraft featuring Delta One Suites, Delta Premium Select, Delta Comfort+ and Main Cabin services. Delta will also start a new daily service between Honolulu and Haneda on Dec. 1. This is the first time Delta has offered service from Haneda to Honolulu with its start delayed due to the pandemic. Customers will be able to enjoy Delta One, Delta Premium Select, Delta Comfort + and Main Cabin services using the Boeing 767-300ER. Reference Link

12:34 EDT Vale fined BRL86.3M in Brazil over Brumadinho dam disclosures - Vale said that Brazil's Office of the Comptroller General concluded that Vale failed to present reliable information to the National Mining Agency in relation to Dam I in Brumadinho/MG and that it was issued a positive Stability Condition Statement for the structure, from June to September 2018, when, in the understanding of the CGU, it should be negative, circumstances that constituted an harmful act to the Public Administration by hindering the inspection of the mining authority. Thus, based on item V of art. 5 of Law No. 12,846/2013 - even recognizing the non-existence of corruption acts - the CGU defined the fine in approximately BRL 86.3M, the minimum baseline established by law, recognizing the non-involvement or tolerance of the top management. The CGU determined the extraordinary publication of its decision, for a period of 30 days, pursuant to article 6, items I and II, of Law No. 12,846/2013. Vale said it disagrees with the decision and will submit a request for reconsideration within the next 10 days to the Minister of State for the Comptroller General of the Union.

12:03 EDT Holland America Line simplifies COVID-19 procedures - Holland America Line is updating its "Travel Well" COVID-19 protocols and procedures, including requirements for vaccinations and pre-cruise testing that meet public health goals while recognizing the evolving nature of the COVID-19 situation. These changes will go into effect for cruises departing on or after Sept. 6, 2022. Holland America Line is updating its "Travel Well" COVID-19 protocols and procedures. Under the simplified procedures, for most voyages up to 15 nights, vaccinated guests will no longer have to test before cruising and unvaccinated guests will be welcomed with a self-test within three days of sailing. The new protocols do not apply to itineraries for countries where local regulations may vary, including Canada, Australia and Greece.

12:00 EDT Turquoise Hill falls -10.4% - Turquoise Hill is down -10.4%, or -$2.72 to $23.53.

12:00 EDT Enhabit rises 16.0% - Enhabit is up 16.0%, or $2.21 to $16.04.

12:00 EDT Revlon rises 22.6% - Revlon is up 22.6%, or $1.48 to $8.04.

11:54 EDT Take-Two's Private Division to publish Middle-Earth game - Take-Two's Private Division announced that it is partnering with Weta Workshop to publish a new video game set in J.R.R. Tolkien's Middle-Earth universe. Middle-Earth is the setting for "Lord of the Rings" franchise, The Fly notes. Reference Link

11:53 EDT Correct:Taseko Mines reports EPA issues draft permit for Florence Copper Project - Taseko Mines announced the U.S. Environmental Protection Agency has publicly issued a draft Underground Injection Control permit for its Florence Copper Project. The EPA has stated that the public comment period for the draft federal permit will last 45 days, ending on September 29, with a virtual public hearing to be held on September 15.

11:31 EDT Rite Aid, WellSpan enter partnership for Central Pennsylvania - Rite Aid and WellSpan Health announced they have established a partnership to improve health outcomes for WellSpan's patient population. Together, Rite Aid and WellSpan Health will share data and insights to close gaps in care and improve continuity across a broader continuum of services, increase immunizations, strengthen medication adherence, and promote in-store opportunities to educate customers on products and services that improve overall health and wellness. The collaboration is anticipated to include clinical services including preventative medicine and chronic disease management and innovative care models designed to improve access to care, quality, and reduce healthcare costs.

11:08 EDT Canadian Pacific announces new two-year collective agreement with TCRC-T&E - Canadian Pacific Railway announced a new two-year collective agreement with the Teamsters Canada Rail Conference - TCRC - Train and Engine following binding arbitration. "The new agreement includes a 3.5% wage increase in 2022 and 2023 and increased benefits. Under the arbitration decision, the TCRC will also join a CP Pension Improvement Account. The new collective agreement runs through 2023," Canadian Pacific stated. "CP welcomes the conclusion of arbitration and is pleased to have completed this agreement with the TCRC Negotiating Committee. We continue to work with our union partners to reach agreements that meet the needs of our industry-leading railroaders and allow us to grow our business as we provide essential services for our customers and the North American supply chain," added CP President and CEO Keith Creel.

11:06 EDT University of Phoenix enters agreement with MedCerts - University of Phoenix announces a new agreement with MedCerts to create educational opportunities for students and employees in healthcare and information technology, and a talent pipeline and upskill system for employers. MedCerts offers unique training options for healthcare and IT employers to reskill and train staff for in-demand roles. The agreement with University of Phoenix allows learners to access a broad set of educational options.

11:03 EDT PowerSchool appoints Fred Studer as CMO - PowerSchool announced the appointment of Fred Studer as Chief Marketing Officer. Studer will lead PowerSchool's Marketing team in developing and executing the strategic direction of the PowerSchool brand, corporate communications, demand generation, and solution marketing.Studer brings more than three decades of experience leading marketing teams, including as CMO at Tibco Corporation.

10:40 EDT EVI Industries to acquire Aldric Clean-Tech Equipment Corp., terms not disclosed - EVI Industries announced that it executed a definitive agreement to acquire Aldrich Clean-Tech Equipment Corp., a Massachusetts based distributor of commercial laundry products and a provider of related installation and maintenance services to commercial laundry customers. This acquisition expands EVI's sales and service presence with the addition of eight commercial laundry technicians and support staff that will enhance EVI's capabilities to its growing customer base across the northeast region of the United States. The transaction is expected to close in the next thirty days or upon the satisfaction of all customary closing conditions.

10:26 EDT Third Point identifies potential board members for Disney board - Third Point said, "Disney is a world-class company that deserves a world-class board of directors who possess diverse talents and experience with strengths in technology, advertising, and consumer engagement, as well as proven track records of leading large complex organizations and creating shareholder value. This is not meant to single out any current board members, but we believe there are gaps in talent and experience as a group that must be addressed. Third Point has identified potential board members who we believe would make essential contributions to the Company's Board at this critical time. We would be happy to make an introduction."

10:24 EDT Third Point urges Disney to acquire Comcast's Hulu stake prior to deadline - Third Point said, "We believe that integrating Hulu directly into the Disney+ DTC platform will provide significant cost and revenue synergies, ultimately reigniting growth in the domestic market. We urge the Company to make every attempt to acquire Comcast's remaining minority stake prior to the contractual deadline in early 2024. We believe that it would even be prudent for Disney to pay a modest premium to accelerate the integration but are cognizant that the seller may have an unreasonable price expectation at this time while noting the seller has already made the decision to prematurely remove their own content from the platform. We know this is a priority for you and hope there is a deal to be had before Comcast is contractually obligated to do so in about 18 months."

10:21 EDT Third Point calls on Disney to embark on cost cutting program - Third Point said, "Disney's costs are among the highest in the industry, and we believe Disney significantly underearns relative to its potential. We urge the Company to embark on a cost cutting program that addresses both margins and the disposal of excess underperforming assets."

10:16 EDT Two Harbors appoints Nicholas Letica as chief investment officer - Two Harbors Investment announced the appointment of Nicholas Letica as Chief Investment Officer to lead the company's Investment and Hedging Strategy. He will report directly to William Greenberg, President and CEO, who previously also held the role of Chief Investment Officer.

10:00 EDT JANA Partners exits Zendesk, boosts stake in New Relic - JANA Partners disclosed in an SEC filing its holdings as of June 30, 2022. JANA exited one position during the quarter, Zendesk (ZEN). JANA increased its stake in four holdings, including by size of previous position, New Relic (NEWR), Laboratory Corp. of America (LH), and Encompass Health (EHC). JANA reduced its stake in one holding, Conagra (CAG). JANA's top holdings as of June 30, in order of size, were TreeHouse (THS), Mercury Systems (MRCY), Laboratory Corp. of America, and New Relic.

10:00 EDT W&T Offshore falls -10.2% - W&T Offshore is down -10.2%, or -63c to $5.53.

10:00 EDT Weber rises 7.5% - Weber is up 7.5%, or 52c to $7.44.

10:00 EDT ironSource rises 11.7% - ironSource is up 11.7%, or 47c to $4.48.

09:47 EDT SEACOR Marine Holdings falls -9.1% - SEACOR Marine Holdings is down -9.1%, or -59c to $5.91.

09:47 EDT Turquoise Hill falls -17.0% - Turquoise Hill is down -17.0%, or -$4.45 to $21.80.

09:47 EDT Blue Apron rises 11.5% - Blue Apron is up 11.5%, or 44c to $4.25.

09:42 EDT Viridian Therapeutics trading resumes

09:38 EDT IDEAYA Biosciences trading resumes

09:37 EDT Viridian Therapeutics trading halted, volatility trading pause

09:34 EDT MDXH Stock trading halted, volatility trading pause

09:32 EDT Goodfood Market expands on-demand delivery in Montreal - Goodfood Market is expanding its On-Demand delivery service in Montreal to include beer and wine from local breweries and Quebec-based wineries. The new offer launched in downtown Montreal and will be expanding to more neighbourhoods in the coming weeks. Residents in Montreal will be able to enjoy a selection of cold beer and wine to go along with the chef-curated meals and inspiring products Goodfood already delivers.

09:26 EDT EV Biologics launches Excyte with $100M valuation - EV Biologics announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation. Excyte has already raised $500,000 of its $2.5 million initial capitalization goal. This funding will initially provide scale-down biomanufacturing process development and important bioanalytical data to advance EV Biologics' ongoing nanotherapeutic development. Funds allocated to comparative evaluation of small-scale automated bioreactor platforms will enable development of scalable biomanufacturing of stem cell-derived nanotherapeutics. The remainder of these funds will be allocated to analysis of the biomolecular composition and the biological activity of the composite secretome products and constituent vesicular and non-vesicular nanoparticle fractions produced by mesenchymal stem/stromal cell banks already isolated and expanded by EV Biologics. Excyte will be focused on innovation in biomanufacturing, bioengineering, bioanalytics and machine learning toward a versatile platform for on-demand precision nanotherapeutic development for any clinical indication. Excyte will take a very pragmatic approach to innovation in the longevity space with accelerated development of products and technologies that can be further commercialized in parallel with its primary development pathway. The Company will use virtual infrastructure and collaboration with best-in-class commercial partners to execute its biotechnology innovations and minimize capital requirements and operating costs. Intellectual property, patents, proprietary process and product development will be held by Excyte in support of EV Biologics.

09:19 EDT Turquoise Hill down 17% after terminating review to be bought by Rio Tinto

09:17 EDT Kohl's appoints Christie Raymond as chief marketing officer - Kohl's announced that Christie Raymond has been named Kohl's chief marketing officer, reporting directly to CEO Michelle Gass. Raymond joined Kohl's in 2017 as senior vice president, media and personalization, and was promoted to executive vice president, customer engagement, analytics & insights in June 2020. She has been acting as the interim chief marketing officer since May.

09:14 EDT Bed Bath & Beyond up another 16.5% amid increase in StockTwits message volume - Shares of Bed Bath & Beyond are up another 16.5% at $15.08 per share in pre-market trading following Friday's gains of 21.8%. The stock is in the top-five highest trending names on StockTwits in terms of message volume over the past 24 hours.

09:14 EDT Fresh Vine announces new strategic growth plan - Fresh Vine Wine announced that, under its new leadership team, it has entered into distribution agreements with four of the nation's leading retailers, with Fresh Vine Wine's varietals hitting the shelves as part of their respective Fall resets. These new retail relationships are a reflection of one of the recent strategic initiatives new leadership has initiated to accelerate growth and minimize time to positive cash flow while preserving cash. Separately, the company today filed with the SEC its 10Q for the second quarter and period ended June 30, 2022. Damian Novak, Executive Chairman of Fresh Vine Wine, said, "Today, we are announcing a number of strategic initiatives that leverage our unique market position, better capitalize on the awareness generated by our celebrity owners, Nina Dobrev and Julianne Hough, and build upon our rapidly expanding national presence. Most importantly, four national, big box retailers have indicated their definitive plans to include Fresh Vine Wines in their Fall resets, beginning in September. Concurrently, we have taken a critical lens to our business and identified opportunities to improve performance in ways that allow us to better meet investor expectations. This includes promoting Rick Nechio to interim CEO and initiating performance improvement measures that reduce our remaining 2022 five month run rate expenses by more than $6 million through the balance of calendar year 2022. Additionally, we added more than $3 million of wine to inventory during the quarter, strengthening our balance sheet and allowing the company to meet strong second half demand and providing significant liquidity as the company converts its current assets to cash. The net result is that we now have a clear path to a positive cash position and are simultaneously preserving capital for further implementation of our strategy."

09:12 EDT Verizon, Hi-Rez team to give Rogue Company players improved mobile experience - Verizon and Hi-Rez are offering an enhanced mobile experience in Hi-Rez's new game, Rogue Company Elite. Players on Verizon 5G Ultra Wideband will be able to download a high fidelity graphics package at fast speeds and with Verizon Up, they can receive a free weapon wrap for use in the game. "Verizon, the network America relies on, is built for gaming, with super-fast speeds, massive capacity and low lag on 5G Ultra Wideband, so you never miss a moment of the action when you're on the go," said Erin McPherson, Head of Consumer Content and Partnerships at Verizon. "With entertainment partners like Hi-Rez, we continue to bring the best experiences to our customers wherever they are - like games you can download in seconds and stream, and the ability to play data-intensive, multiplayer games typically reserved for consoles on your mobile phone."

09:11 EDT Grocery Outlet, DoorDash partner for on-demand grocery delivery - Grocery Outlet (GO) announced a partnership with DoorDash (DASH) to offer on-demand grocery delivery from more than 398 locations across the country including Pennsylvania, New Jersey, Maryland, California, Washington, Oregon, Idaho, and Nevada. Now DoorDash customers can order groceries on-demand from local Grocery Outlet stores via the DoorDash marketplace app or website. "DoorDash is committed to providing customers with all the selection they crave at affordable prices, in a way that's convenient for them and their families," said Shanna Preve, Vice President, Business Development at DoorDash. "As consumers face rising prices, we're thrilled to partner with Grocery Outlet to provide consumers across the country with a new way to purchase more affordable groceries while maximizing their budgets. With this partnership, consumers can find and enjoy even more affordable grocery selection on our marketplace."

09:09 EDT Freight Technologies provides company update - Freight Technologies filed a Form F-1 with the SEC. "We are incredibly proud of our team, and thank them for their work and dedication to deliver our F-1 registration, which positions us to be able to continue to grow as a public company. Delivering our registration statement puts us in a position to continue to work with the capital markets to foster the growth of our company," Javier Selgas, CEO of Fr8Tech, said, "Our U.S. domestic Fr8App services are gaining traction. Our dedicated capacity product, Fr8Fleet, is deepening our existing relationships in Mexico as well as garnering additional opportunities in both countries. By investing in new product development to further expand our presence cross-border as well as in the U.S. and Mexico, we are poised to capture greater market share and create additional shareholder value."

09:09 EDT Outset Medical awarded national contract from SAC for Tablo Hemodialysis System - Outset Medical announced that the Strategic Acquisition Center, or SAC, Office of Procurement, Department of Veterans Affairs awarded a national contract that enables the company's Tablo Hemodialysis System to be sold into the 106 VA hospitals in the U.S. VA medical facilities across the U.S. provide dialysis care for 35,000 veterans. While Tablo is already deployed in some of those facilities, the new five-year contract will enable VA centers to acquire consoles to send veterans home and expand usage in the acute setting. The award provides for an indefinite quantity of services and goods during the Indefinite Delivery Indefinite Quantity, or IDIQ, Award Contract. As part of one of the three centralized contracting entities within the VA, the SAC has been tasked to create superior procurement solutions that deliver on the VA's promise to veterans.

09:07 EDT Crestwood Equity promotes John Black to CFO - Crestwood Equity Partners announced a series of executive leadership promotions, effective immediately. John Black has been promoted to executive VP and CFO and will report directly to Robert Halpin, who will continue in his role as president and report directly to Robert Phillips, founder, chairman and CEO. Black has been with Crestwood since 2014, most recently serving as senior VP, finance since 2019.

09:06 EDT Take-Two unit Private Division in publishing pact with Weta Workshop - Private Division, a publishing label of Take-Two Interactive Software, announced they have signed a new publishing agreement with Weta Workshop, best known for their work on Middle-earth for The Lord of the Rings film trilogy. In 2014 Weta Workshop founded an interactive game division and are now developing a new game set in the Middle-earth universe of J.R.R. Tolkien. Middle-earth Enterprises have licensed the literary works of the series, providing Weta Workshop with the broadest creative license to interpret the underlying lore of the books. "We are thrilled to partner with Weta Workshop to publish a game set in such an extraordinary and celebrated universe," said Michael Worosz, Chief Strategy Officer, Take-Two Interactive, and Head of Private Division. "The Lord of the Rings IP is home to so many remarkable stories, and no entity is better equipped than the team at Weta Workshop to create a distinctive, new Middle-earth gaming experience."

09:02 EDT IPG Photonics sells telecom transmission product lines to Lumentum - IPG Photonics Corporation (IPGP) announced that it has sold its telecom transmission product lines, comprised of optical transceivers and coherent components, to Lumentum (LITE). The divested activities include the former Menara Networks and a subsidiary in Brazil. The sale will have an immaterial effect on the Company's total revenue and earnings per share, but is expected to reduce R&D spending and operating expenses going forward. The reduction will help to offset some inflationary pressures, including merit increases, impacting the rest of the year. Details of the transaction were not disclosed. Centerview Partners LLC served as financial advisor and Locke Lord LLP served as legal counsel to IPG Photonics in the transaction.

09:02 EDT Personalis announces collaboration with BC Cancer to deploy RUO assay - Personalis announced a collaboration with BC Cancer to deploy a personalized liquid biopsy-based research use only, or RUO, assay for a study of patients with colorectal and pancreatic cancers. The research efforts will deploy Personalis' NeXT Personal, which has demonstrated high sensitivity for detecting circulating tumor DNA, or ctDNA, from a patient's blood sample, to determine the best time to draw blood for ctDNA sampling for molecular residual disease, or MRD, detection. MRD describes a very small number of cancer cells that remain in the body during or after treatment.

09:00 EDT AMMO trading resumes

08:49 EDT Neogames' BtoBet enters sportsbook partnership with SOJOGO - NeoGames subsidiary BtoBet has announced a multi-year partnership agreement with SOJOGO and Santa Casa Global, the global arm of the Portuguese National Lottery Santa Casa da Misericordia de Lisboa. Through this partnership BtoBet will be providing SOJOGO with its proprietary sportsbook offering for both its online operations and retail network.

08:47 EDT Equus Total Return reports Q2 NAV per share $2.75 - During the second quarter of 2022, the fair value of Equus Energy, LLC, increased from $15.0 million to $15.5 million. Among the various leasehold rights held by Equus Energy is a 50% working interest in 2,400 acres in the Permian Basin known as the Conger Field. A number of transactions that completed in 2021 and the first half of 2022 were concentrated in the Permian Basin, at imputed acreage values considerably in excess of values ascribed to such acreage in the past several years. In addition, West Texas Intermediate crude prices increased from $100.28 per barrel at March 31, 2022 to $105.76 per barrel at June 30, 2022, an increase of approximately 5.46%, while natural gas prices increased from $5.46 per MMBTU at March 31, 2022 to $6.54 per MMBTU at the end of the second quarter of 2022, which was an increase of approximately 19.8%. Equus also holds working interests of 7.5% and 2.5% in the Burnell and North Pettus Units, respectively, which collectively comprise approximately 13,000 acres located in the area known as the 'Eagle Ford Shale' play. The Company received advice and assistance from a third-party valuation firm to support its determination of the fair value of this investment.

08:46 EDT Quantum Computing releases video demonstrating recent achievement in the field - Quantum Computing shared a video demonstrating what it believes is a "landmark achievement" in the field. In the video, QCI CTO/COO William McGann reveals that the Company has solved a sensor optimization problem with over 3,800 variables including 500 constraints in just over six minutes. This achievement demonstrates the first full-quantum solution, delivering a feasible and optimal result that is superior to previous comparative classical and hybrid approaches. The video also features Dr. McGann presenting data that shows full quantum solutions are available today. As outlined in the video, QCI applied its new quantum hardware technology called Entropy Quantum Computing to the public Quantum Computing Challenge hosted and organized by the BMW Group. In comparison to QCI's achievement, today's Noisy Intermediate Scale Quantum computers can only process ~127 variables for a problem of similar complexity. "Many quantum companies have predicted the timeline of pure quantum solutions solving real and complex business problems is about 3-5 years away. We believe we have proven that the day has already arrived," said Robert Liscouski, CEO, QCI. "This is the sunrise of a new era in computing, in which we believe that quantum will be the primary means of solving many of the most complicated and critical problems facing business."

08:45 EDT Navitas Semiconductor announces OnePlus selects GaNFast ICs for smartphone - Navitas Semiconductor announced that OnePlus has once again chosen GaNFast next-gen power ICs to ultra-fast-charge its new flagship smartphone, the OnePlus 10T. The new OnePlus 10T features the latest Qualcomm Snapdragon 8+ Gen 1 chipset, a 120 Hz FHD + AMOLED display screen, and 50 MP main camera, with advanced Cryo-Velocity Vapor cooling, all driven by a powerful 4,800 mAhr battery. The 150W-capable SUPERVOOC Endurance Edition delivers up to a day's power after just 10 minutes of charging, with a full charge -from 1-100% -taking only 19 minutes.

08:43 EDT Navitas Semiconductor to present next-gen semiconductors at fireside chat - Navitas Semiconductor announced its participation in the Taiwan Investor Fireside Chat hosted by Mesh Ventures. The virtual meeting is scheduled for Thursday, August 18th at 9:30 p.m. US EDT / Friday, August 19th at 9:30 a.m. in Taiwan. GaN is a next-generation semiconductor technology that runs up to 20x faster than legacy silicon and enables up to 3x more power and 3x faster charging, with up to 40% energy savings, in half the size and weight. Navitas' GaNFast power ICs with GaNSense technology integrate GaN power and drive, plus control, sensing, and protection to deliver simple, small, fast, and efficient performance. Customers include Samsung, Dell, Lenovo, Xiaomi, OPPO, Anker, Amazon, and LG. With over 165 patents issued or pending and significant trade secrets, including a proprietary process design kit, Navitas believes it has a multi-year lead in next-generation GaN power ICs.

08:42 EDT SciSparc signs non-binding LOI to acquire foods, cosmetic brand for $20M - SciSparc announced that it has signed a non-binding letter of intent with Merhavit M.R.M Holding and Management, to acquire from it its rights to purchase, a top-seller Amazon.com account and American food supplements and cosmetics brand and trademark. The Brand offers dozens of GMP manufactured hemp-based, U.S. made, top-ranked products, including various food supplements for different purposes and cosmetics. The LOI also describes, in addition to the potential acquisition of the Brand, a management agreement to be entered into and an option to expand the brand to additional territories such as Canada and Europe, as well as a distribution agreement with a local U.S. distributor, which shall provide for a minimum initial order of the Brand's products for $100,000 upon its execution. Upon entry into definitive documentation, the management agreement is expected to include fulfilment of the Amazon.com conditions, manufacturing, inventory and advertising management, storage and shipment to the Amazon.com warehouse, and maintaining a pre-determined profit level for the products. As contemplated by the LOI, subject to signing a definitive agreement, SciSparc will pay a base payment of $4.59 million upon closing of the transaction and an additional deferred cash payment of up to $1.1 million that will be based on a multiple of 12 months EBITDA of the acquired Brand. In addition, the Company will grant to M.R.M $15M worth of warrants to purchase ordinary shares of SciSparc at an exercise price of $7.00 per share and with an exercise period of five years from the closing of the definitive transaction. The Warrants will become exercisable upon the achievement of a milestone of $100M of sales in the aggregate or if the price of SciSparc's ordinary shares closes at $10.00 or above.

08:40 EDT ContraFect reduces workforce by 16 employees, or 37% of headcount - In order to be positioned to initiate the potential clinical trials, the Company has taken multiple actions to maximize its resources and focus its efforts on the execution of its corporate strategy. Subsequent to the Data Safety Monitoring Board recommendation, disclosed in the Company's press release issued and 8-K filed with the Securities and Exchange Commission on July 13, 2022, that the Phase 3 DISRUPT trial be stopped for futility, the Company has implemented the following actions: The Company initiated and has completed a significant portion of its own analyses of the accrued DISRUPT study data and expects to complete the analysis toward the end of the third quarter of 2022. The Company expects that conclusions drawn from the ongoing data review will inform next steps for any potential further development of exebacase. Investigators were notified of the DSMB recommendation and that new patient enrollment in the trials was being stopped. The Company expects the final patients already enrolled in the study at the time of the DSMB recommendation to complete their follow-up visits in September. The Company also expects to complete all clinical study reports as required by the FDA. All CMC activities related to the potential commercialization of IV exebacase have been or are in the process of being suspended. The Company has reduced its workforce by 16 employees, or approximately 37% of the Company's headcount as of June 30, 2022. The Company expects to recognize a restructuring charge in the third quarter of 2022 of approximately $1.5 million consisting primarily of severance, one-time termination and other related costs, all of which will result in future cash expenditures. The Company expects this headcount reduction to lower its annual operating costs by over $4.0 million. This reduction includes the resignation of Cara Cassino, M.D. as Chief Medical Officer and Executive Vice President of Research and Development of the Company. Dr. Cassino's resignation as an officer of the Company was effective on August 14, 2022. Finally, the Company has engaged Garrett Nichols, M.D., M.S., to be its Interim Chief Medical Officer.

08:38 EDT PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital - PharmaCyte Biotech announced that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCyte's outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois' director designees to PharmaCyte's reconstituted Board of Directors. Pursuant to the Agreement, Iroquois' director designees, Jonathan L. Schechter and Joshua N. Silverman, will join PharmaCyte's reconstituted Board as independent directors. Jack E. Stover, Daniel S. Farb, and Daniel C. Allen will also join PharmaCyte's reconstituted Board as independent directors. Existing PharmaCyte directors Kenneth L. Waggoner and Dr. Michael M. Abecassis will complete the 7-member Board. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, commented, "We are pleased to have reached this constructive agreement with Iroquois which we believe is in the best interest of all shareholders. Our reconstituted Board combines extensive science, operating and capital markets experience that will make PharmaCyte a much stronger company. I would like to thank all of our previous Board members for their numerous and invaluable contributions, including Dr. Matthias Lohr, Dr. Gerald W. Crabtree, Thomas Liquard, Dr. Raymond C.F. Tong and Carlos Trujillo. Each resigned from the Board as part of the Cooperation Agreement after determining that the Cooperation Agreement, including the composition of the new Board, was in the best interest of the Company moving forward. "We are nearing the end of our process to fulfill the FDA's requests to enable the clinical hold to be lifted. To date, approximately 90% of the FDA's requests have been completed or are in process with one major pig study remaining to be completed. We look forward to integrating our new directors' ideas to drive our continued development and growth as a Nasdaq biotechnology company focused on developing treatments for hard-to-treat diseases like cancer, diabetes, and malignant ascites."

08:35 EDT AMMO to separate ammunition, marketplace businesses into two public companies - AMMO announces that its Board of Directors has unanimously approved a plan to separate its ammunition and marketplace businesses into two independent publicly-traded companies. Outdoor Online will be comprised of GunBroker.com and its related online businesses. Current AMMO Chairman & CEO, Fred Wagenhals, will assume the Chairman & CEO role in Outdoor Online. The second entity, Action Outdoor Sports, will retain the Company's current ammunition and munition components business, including its well- established STREAK, Signature, Blackline, /stelTH/, Blueline AMMO Brass, and Hunt Ammunition brands. The AOS CEO, executive management team and board of directors will be announced at a later date and in advance of consummation of this transformational transaction, anticipated to close during calendar 2023. The Company expects to create these companies through a tax-free spin-off by AMMO of AOS. The Company believes there are a number of compelling reasons supporting the separation of these two vibrant business units, including: Better Positioned to Enhance Shareholder Value: Compelling and distinct investment opportunities derived from each particular business model. As independent and separate companies, AMMO expects each will be better situated to be appropriately valued by the market. Enhancement of Brand Strength: The separation and renewed focus by each newly organized business is expected to facilitate the enhancement and expansion of the valuable brand strength developed in both separate operational units, thus further supporting increased enterprise and therefore shareholder value. Prioritize and Refine Capital Allocation: With separated business models and short- and long-term goals, each company will be better positioned to refine and focus capital allocation strategies moving forward. Expanded Strategic Opportunities: With a renewed focus, AOS will build upon AMMO's well-established track record as an attractive acquirer through enhanced M&A work in the outdoor recreation marketplace, allowing it to secure best-in-class partnerships with other manufacturers. Similarly, Outdoor Online will be best positioned to focus on continuing the work designed to leverage its leading marketplace, while focusing on potential accretive M&A opportunities specific to its space and market. Reinforce and Amplify the Ability to Attract and Retain Top Market Talent: Each company's short- and long-term objectives will be enhanced by a renewed ability to attract and retain the top industry talent best situated for each business' operation separate operational and financial objectives. Enhanced Strategic Focus with Supporting Resources: Financial and human capital resources will be deployed in a focused manner to best support the specific operational needs and growth drivers of each separate company. Following the spin-off, AOS will operate as the one of the fastest growing U.S. based ammunition and munition components manufacturers through ramped up operation within its new best-in-class and cutting-edge plant located in Manitowoc, Wisc. Through scaled up operations within this exciting new plant, the newly formed company plans to incrementally expand production in due course to approximately 1 billion loaded rounds of ammunition to support the manufacture and sale of its patented STREAK Visual Ammunition, /stelTH/ subsonic munitions, and specialty rounds for military and law enforcement use via government programs. AOS will be best situated to enhance operational efficiencies via the new plant as it drives growth and cash flow through leveraging AMMO's profound customer relationships and operational expertise. AMMO's analysis of the separation of these distinct business units on a go-forward pro forma basis results in projected 2023 AOS Fiscal Year guidance of $230 -$240 million in revenue and $57 - $60 million in Adjusted EBITDA. This transformational plan and relocation into the new plant will also best position the company to support its military program partners with the cutting-edge products requested by component groups within the US Special Forces community and its ally partners, manufactured to exceptional tolerance and produced at the necessary volume. The resulting company will also be situated to enhance support of AMMO's growing base of international customers. Fred Wagenhals will serve as the Chairman. The Company will announce the appointment of the AOS Chief Executive Officer and compliment of management team members at a later date. The AOS corporate operations will remain headquartered in Scottsdale, Ariz., with manufacturing operations based in Manitowoc, Wisc. AMMO acquired GunBroker.com, its suite of subsidiaries, and its industry-leading online Marketplace in April 2021. The business has maintained its industry leader position as AMMO has worked to enhance customer service and the seller and buyer experience, while leveraging the site with increased Marketplace offerings. Following the spin-off, Outdoor Online will hold and operate the GunBroker.com online Marketplace and related high-margin and asset-light business assets and operations. AMMO's analysis of the separation of this business unit on a go-forward pro forma basis results in projected 2023 Outdoor Online Fiscal Year guidance of approximately $70 million in revenue, $51 million in Adjusted EBITDA, with plans to further leverage the Marketplace through augmentation of the platform to drive additional growth and profitability. Fred Wagenhals will serve as the Outdoor Online Chairman & CEO following the spin-off. The Company will announce the management team members at a later date which management team will be comprised of select current AMMO executives and industry leaders currently engaged within the space and also announce the headquarters' location. AMMO anticipates the transaction will be in the form of a dividend distribution to its shareholders of 100% of the stock of AOS, which will become a new, independent publicly traded company. The distribution is intended to be tax-free to both companies and their shareholders for U.S. federal income tax purposes. Concurrently, AMMO will change its name to Outdoor Online and will operate under a new ticker symbol. As of this date, AMMO reasonably anticipates the transaction will be completed in the 2023 calendar year, subject to final approval by the Company's Board of Directors, a Form 10 registration statement being declared effective by the U.S. Securities and Exchange Commission, regulatory approvals and satisfaction of other standard and necessary terms and conditions. There can be no assurance the transaction will be consummated or as concerns the ultimate timing of the proposed transaction.

08:32 EDT Yum China files for voluntary conversion to primary listing on HKEX - Yum China announced that the company applied for a voluntary conversion of its secondary listing status to a primary listing status on the Main Board of The Stock Exchange of Hong Kong Limited. On August 15, the company received the acknowledgement from the HKEX in respect of the application for the Proposed Primary Conversion. To comply with the Hong Kong listing rules applicable to a dual primary listed issuer, the company will call a Special Meeting of Stockholders to be held on October 11, Beijing/Hong Kong time, to seek stockholder approval on certain proposed items. Conditional upon and subject to receiving stockholder approval on all proposed items at the Special Meeting and obtaining the necessary approvals from the HKEX, the company will become dual primary listed on the New York Stock Exchange and the HKEX. The effective date of the Proposed Primary Conversion is expected to be October 24. The company's common stock on the two exchanges will continue to be fully fungible and investors can continue to choose to trade their shares on either stock exchange.

08:29 EDT Base Carbon reports total assets of $56.4M as of June 30 - During the second quarter of 2022, amongst other achievements, the Company announced the execution of a carbon reduction project involving the distribution of 850,000 cookstoves and 364,000 water purifiers in Vietnam. Base Carbon facilitated a contractual project offtake agreement for initial carbon credit production which is anticipated to result in a payback period of 2.75 years on aggregate capital deployed. The distribution of the devices in Vietnam is expected to be completed by mid 2023, ahead of schedule, with approximately 285,000 devices having been distributed to date. The distribution of cookstoves as part of the Company's initial carbon reduction project in Rwanda is also outperforming initial project timelines with full deployment of cookstoves currently expected by the end of 2022.

08:27 EDT SPX Corporation completes legal structure reorganization - SPX Technologies announced that it has finalized the reorganization of its corporate legal structure, pursuant to Section 251(g) of the Delaware General Corporation Law. The reorganization included a tax-free merger of SPX Corporation with and into SPX Merger, LLC, a newly-formed Delaware limited liability company that is a subsidiary of a newly-formed Delaware corporation, SPX Technologies, Inc. As a result of the transaction, SPX Technologies has become the holding company for the SPX group of companies, and now will be the publicly traded entity. The SPX common stock will continue to trade on the NYSE on an uninterrupted basis with no change to the ticker symbol "SPXC." The stock will trade under a new CUSIP.

08:26 EDT Greenrose Acquisition postpones Q2 conference call - The Greenrose Holding Company announced that it will be postponing its scheduled conference call on Monday, August 15, 2022, at 5:00 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022. Greenrose is committed to reporting its second quarter 2022 financial results and providing an update on timing for the rescheduled conference call as soon as practicable. The Company expects to issue revised call details once confirmed.

08:25 EDT Outlook Therapeutics appoints Haller to board of directors - Outlook Therapeutics announced the appointment of Julia Haller, MD, to the Company's Board of Directors. Julia Haller, MD is the Ophthalmologist-in-Chief at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University.

08:23 EDT Society Pass announces acquisition of NusaTrip - Society Pass announces the acquisition of NusaTrip, a leading Jakarta-based Online Travel Agency in Indonesia and across SEA. The NusaTrip acquisition extends SoPa's business reach into the booming SEA regional travel industryand marks SoPa's first foray into Indonesia as well as adds to SoPa's growing ecosystem of technology-enabled companies located in Vietnam, Indonesia, Philippines, Singapore and Thailand. Dennis Nguyen, Society Pass Founder, Chairman and Chief Executive Officer, explains, "We happily welcome NusaTrip into our ever-expanding SoPa ecosystem. NusaTrip seamlessly blends into our user and merchant growth strategy as we enter yet another leading SEA market. We combine the robust technology and operational breadth of NusaTrip's e-commerce travel platform with our extensive brand building experience in SEA. With this acquisition, SoPa now cross-pollinates and integrates our six verticals (loyalty, lifestyle, food & beverage, telecoms, digital media and travel) into one cohesive loyalty and e-commerce platform to provide enhanced products and services for our consumers and merchants throughout the largest countries of SEA. SoPa has grown from strength to strength in 2022 as we opportunistically acquire market leading companies and partner with visionary entrepreneurs, underlining our unique aggregator approach that reflects immediate returns in terms of increased revenue generation and cost optimization."

08:22 EDT Amarin announces new research on effects of VASCEPA/VAZKEPA - Amarin Corporation announced new supported and/or funded research on the effects of VASCEPA/VAZKEPA in specific patient subgroups at increased risk of a cardiovascular event from the landmark REDUCE-IT cardiovascular outcomes trial have been accepted for presentation at the European Society of Cardiology Congress, both online and onsite in Barcelona, August 26-29, 2022. The accepted abstracts include a Late-Breaking Science presentation on reduction of ST-segment Elevation MI with VASCEPA from the REDUCE-IT trial. These and other new findings will be presented by a variety of international academic collaborators based on research or analyses supported by Amarin. "We are pleased to support these Late Breaking Science and Oral Presentations at the upcoming ESC Congress being held later this month," said Nabil Abadir, MB. CH.B., SVP, Chief Medical Officer and Head of Global Medical Affairs, Amarin. "These data continue to underscore the clinical and therapeutic utility and value of VASCEPA/VAZKEPA and continue to validate the clinical outcomes shown in the overall REDUCE-IT trial. As we know, REDUCE-IT demonstrated the clear risk reduction benefits of icosapent ethyl in reducing cardiovascular events among patients most at risk for cardiovascular disease including those with previous cardiovascular events, such as myocardial infarction or stroke. We are proud of the continued work that is being done to further demonstrate the proven efficacy of VASCEPA in cardiovascular risk reduction while providing support to investigators to explore other ways in which VASCEPA can potentially help patients and impact public health."

08:20 EDT PowerFleet announces renewal, expansion of partnership with NACPC - PowerFleet announced the renewal and expansion of its partnership with North American Chassis Pool Cooperative, NACPC. Following its recent acquisition of manufacturer Pratt Intermodal Chassis, NACPC has chosen PowerFleet as one of its major technology partners for chassis tracking and monitoring, which enables NACPC to address the extraordinary demand for high-quality chassis with the latest technology to help relieve pressure at ports across the country. The partnership will increase real-time visibility within NACPC's nation-wide network of chassis pools and products, helping customers maximize their equipment utilization. Together with PowerFleet, NACPC is looking to provide its customers with increased value and security. "We're thrilled to continue our long-standing relationship with NACPC as they scale up their chassis technology solutions with us," said Matt Harris, Vice President of Account Management, PowerFleet. "We're proud to work alongside the team at NACPC to come up with the right solutions to address their customers' most important challenge - finding available chassis to keep cargo moving along the supply chain."

08:18 EDT ironSource comments on Unity rejection of AppLovin proposal - ironSource (IS) commented on Unity's (U) announcement that its board of directors has unanimously rejected AppLovin's unilateral, non-binding, all-stock proposal with Unity and reaffirmed its commitment to a merger with ironSource: "Unity's rejection of AppLovin's unilateral bid confirms the superior strategic value of the merger with ironSource. Together, Unity and ironSource will be stronger, more profitable, and better able to optimize both the Create and Operate sides of the business to deliver everything creators need to succeed. The deep synergies driving the ironSource-Unity merger extend across the entirety of both companies' platforms and offerings and underpin our strong financial projections of $1 billion in Adjusted EBITDA by the end of 2024 and $300 million in annual EBITDA synergies by year three. The Board of Directors of ironSource remains committed to completing this strategically and financially compelling combination in the fourth quarter of this year and is confident it will create superior value for shareholders, customers, and employees."

08:18 EDT Agios Pharmaceuticals appoints Ballal, Smith to board of directors - Agios Pharmaceuticals (AGIO) announced the appointments of Rahul Ballal, Ph.D., chief executive officer of Imara, and Cynthia Smith, former chief commercial officer of ZS Pharma, to its board of directors. Ballal has served as Imara's (IMRA) president and chief executive officer and a member of the board of directors since June 2018.

08:16 EDT Singing Machine launches flagship Karaoke product in Costco US - The Singing Machine Company (MICS) announced it is launching its new flagship WiFi pedestal karaoke machine with Costco (COST) North America and select worldwide territories for this coming fall. The new distribution program will provide distribution into more than 500 Costco US locations nationwide and a wider international distribution plan which includes 40 Costco Clubs in Mexico and 13 Costco Clubs in Australia. Gary Atkinson, Company CEO, commented, "We're excited to launch our new fully-featured, innovative karaoke product line with Costco. Costco members demand the best products in any category they buy and we're honored that our Singing Machine products continue to meet the test of excellence year-in and year-out." Atkinson continued, "This is our third consecutive holiday season where we are building sales momentum with Costco driven off of technological capabilities and new offerings. We launched our digital content subscription model with Costco as a pilot two years ago and built on that momentum with excellent sales results in 2021. We look forward to unveiling our new flagship product with Costco in the next few weeks nationwide.

08:15 EDT Bit Origin completes acquisition of 622 miners - Bit Origin announced that the Company entered into an asset purchase agreement with About Offshore to purchase 622 Antminer S19j pro Bitcoin Miners, which are expected to ramp up the hash rate of the Company's miner fleet by over 62,200 TH/s. Pursuant to the Agreement, the Company agrees to purchase 622 S19j pro Bitcoin Miners for an aggregate value of $3,110,000 in the form of 8,685,574 ordinary shares of the Company, valued at $0.36 per share. These miners will be delivered to the Company's mining facility site in the U.S. The purchase of 622 miners is a part of the intended purchase plan announced through a press release on June 2, 2022. With the newly purchased miners, the Company will increase the total number of Bitcoin Miners to 4,250, producing approximately 403 PH/s when all miners are put in full operation. In theory, it is expected to produce approximately 54 BTCs per month when all miners are deployed. Lucas Wang, Chairman and Chief Executive Officer of the Company, commented, "We are very pleased to complete the purchase of the 622 miners as we continue to progress toward our goal to expand our business and increase our operational capability. Given the situation of the current turbulent market environment, we believe this allows us to acquire high-quality assets with lower costs. With our vision and ability to seize the opportunity, we are confident that the Company is on the right track to improve profitability and create long-term value for our shareholders."

08:13 EDT Codorus Valley Bancorp names Stolzer as General Counsel - Daniel Stolzer, Esq. has been named General Counsel for Codorus Valley Bancorp (CVLY) and its banking subsidiary PeoplesBank. Stolzer has over 40 years of experience in the financial services industry, with expertise in strategic business leadership and navigating corporations through complex legal landscapes. Most recently, Daniel was employed by Fulton Financial Corporation (FULT) as Executive Vice President, Special Projects and M&A.

08:09 EDT Impel NeuroPharma expects cash to fund operations into 2024 - As of June 30, 2022, Impel had approximately $97.8 million in cash and cash equivalents. The Company projects, based on its current operating plan, it has sufficient capital to fund operations into 2024.

08:08 EDT Taseko Mines: FDA issues draft permit for Florence Copper Project - Taseko Mines is pleased to announce the U.S. Environmental Protection Agency has publicly issued a draft Underground Injection Control permit for its Florence Copper Project. The EPA has stated that the public comment period for the draft federal permit will last 45 days, ending on September 29, with a virtual public hearing to be held on September 15.

08:07 EDT Unity announces up to $2.5B share buyback program - In connection with the merger, Unity's board of directors has authorized a 24-month share buyback program of up to $2.5B, effective upon closing of the merger.

08:05 EDT Unity rejects proposal from AppLovin, reaffirms commitment to ironSource deal - Unity (U) announced that its board of directors has completed a financial and strategic evaluation of the unsolicited proposal from AppLovin (APP), with the assistance of outside financial and legal advisors, and has unanimously determined that it is not in the best interests of Unity shareholders and would not reasonably be expected to result in a "Superior Proposal" as defined in Unity's merger agreement with ironSource (IS). The Unity board reaffirmed its recommendation to Unity's shareholders to vote in favor of the previously announced ironSource transaction and recommends against the unsolicited AppLovin proposal.

08:04 EDT Novavax submits application to FDA for EUA for COVID-19 vaccine booster - Novavax announced that it submitted an application to the U.S. FDA for Emergency Use Authorization of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a homologous and heterologous booster in adults aged 18 and older.

08:02 EDT Tempest Therapeutics sees cash runway into 1Q24 - Tempest ended the second quarter of 2022 with $51.6 million in cash and cash equivalents, compared to $51.8 million at December 31, 2021. The decrease was primarily due to cash used in operations of $15.5 million offset by proceeds from the PIPE financing of $14.5 million

07:59 EDT Flowr completes headcount reduction of 40% of workforce - The sale of Flowr Forest marks the completion of first phase of the Company's transformation plan which saw the organization make governance and management changes, divest a series of non-core asset and cut costs to further right-size the organization. Significant recent milestones exclusive of the sale of Flowr Forest include: Completing a headcount reduction necessary in order to flatten its organizational structure and right-size SG&A with revenue. The Company has eliminated 40% of its workforce, largely in senior and middle management, resulting in anticipated annual savings of over $4M.

07:56 EDT Aerovate Therapeutics expects cash to fund operations into 2H25 - The company said, "We expect that our cash, cash equivalents and short-term investments will be sufficient to fund our operations into the second half of 2025, based on our current operating plan. Cash, cash equivalents and short-term investments totaled $152.0 million as of June 30, 2022, compared to $167.4 million as of December 31, 2021. The decrease was primarily driven by operational costs for the six-month period ended June 30, 2022."

07:47 EDT Charge Enterprises announces 2H22, 2023 priorities - The company said, "Charge serves a large addressable market with an urgent need for updated infrastructure at the crossroads of EV Charging and Communications. This combined sector is propelled by strong tailwinds from private and public spending. Charge's mission over the next 18 months remains focused on the execution of being the trusted infrastructure provider in the EV charging and 5G broadband space. The Company's strategy is to integrate and optimize value from high-quality assets with growing recurring revenue streams across its core competencies by: Executing seamlessly for Telecommunications and Infrastructure customers; Broadening its value proposition to meet evolving customer needs, adding capabilities both through internal development and targeted strategic and opportunistic M&A to optimize Charge's competitive edge as a trusted advisor; Proceeding at a measured and methodical pace to build a healthy foundation with refined processes for sustained long-term growth; and Development of new software products and services."

07:43 EDT 9 Meters Biopharma sees cash runway into 4Q23 - Taking into account the initial drawdown of $20 million at closing of the debt facility, the Company would have a pro-forma cash, cash equivalents, and restricted cash balance of $49.5 million as of June 30, 2022, and an expected cash runway into fourth quarter 2023.

07:39 EDT Atai Life Sciences sees cash runway into 2025 - Cash, cash equivalents and short-term investments totaled $312.5 million as of June 30, 2022, compared to $362.3 million as of December 31, 2021. The six-month net decrease of cash of $49.8 million was primarily attributable to net cash used in operating activities of $45.9 million, $3.0 million of additional investments in the platform companies, offset by $1.9 million received from the conversion of promissory notes and equity issuances

07:36 EDT VersaBank receives TSX approval for Normal Course Issuer Bid - VersaBank has received approval from the Toronto Stock Exchange to proceed with a Normal Course Issuer Bid for its common shares. Pursuant to the NCIB, VersaBank may purchase for cancellation up to 1,700,000 of its common shares representing approximately 9.54% of its public float. Daily purchases under the NCIB will be limited to 25% of the ADTV, which is 1,182 common shares, other than block purchase exceptions. The purchases may commence on August 17, 2022 and will terminate on August 16, 2023, or such earlier date as VersaBank may complete its purchases pursuant to the NCIB.

07:35 EDT Quipt announces commitment letter for $80M of senior credit facilities - Quipt Home Medical announced it has received a binding commitment letter from CIT Bank, that CIT will commit to provide 100% of the senior secured credit facilities in the aggregate amount of up to $80,000,000. The Senior Credit Facilities would be evidenced by an Amended and Restated Credit and Guaranty Agreement, which will amend and restate the Credit Agreement dated September 18, 2020 between Quipt and CIT. The primary use of proceeds of the loans made under the Proposed Senior Credit Facilities will be used to finance potential future acquisitions and general working capital purposes. Closing is anticipated to occur within 30 days.

07:32 EDT Vivos Therapeutics to reschedule Q2 conference call - Vivos Therapeutics announced that it will reschedule the release of its financial results for the second quarter ended June 30, 2022 and related conference call, both previously scheduled for Monday, August 15, 2022. Further details for the release of the second quarter financial results and subsequent conference call, expected on or before August 22, 2022, will be provided in a subsequent announcement. The rescheduling is a result of ongoing Company analysis and related discussions between the Company and its independent registered public accountants regarding certain technical matters pertaining to the Company's revenue recognition policies related to ASC Topic 606.

07:28 EDT Moderna receives MHRA authorization of omicron-containing bivalent booster - Moderna announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted conditional authorization for the use of the Omicron-containing bivalent COVID-19 booster vaccine, mRNA-1273.214 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 and a vaccine candidate targeting the Omicron variant of concern. The decision from the MHRA is based on clinical trial data from a phase 2/3 trial, in which mRNA-1273.214 met all primary endpoints, including superior neutralizing antibody response against Omicron when compared to a 50 microgram booster dose of mRNA-1273 in baseline seronegative participants. A booster dose of mRNA-1273.214 increased neutralizing geometric mean titers against Omicron approximately 8-fold above baseline levels. In addition, mRNA-1273.214 elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to the currently authorized booster regardless of prior infection status or age. Moderna is working with The Vaccine Taskforce, UK Health Security Agency, and NHS to make Spikevax Bivalent Original/Omicron available to the UK public. Moderna has completed regulatory submissions for mRNA-1273.214 in Australia, Canada, and the EU and expects further authorization decisions in the coming weeks.

07:24 EDT View Inc. issued statement on Inflation Reduction Act of 2022 - View issued the following statement on the Congress-passed Inflation Reduction Act of 2022: "View applauds Congress for taking the ambitious and necessary steps required to address the climate crisis. The Inflation Reduction Act of 2022 is the largest investment to address climate change in U.S. history. This legislation will unleash clean technology deployment across the country to cut greenhouse gas emissions, reduce energy costs, and create millions of jobs. The legislation includes smart windows alongside solar, wind and storage in Section 48 ITC and is expected to accelerate market adoption of smart windows. Widespread deployment of smart windows will reduce energy consumption of buildings, make the power grid more resilient, improve energy security and create American, cleantech manufacturing jobs. Over the last decade we have witnessed the power of ITC in driving market adoption of other clean technologies, notably wind and solar... This is a watershed moment for the country, for the cleantech industry, and for View. View is on a mission to use technology to solve climate change and improve human health, two of the biggest challenges and opportunities of our times..."

07:21 EDT MKS Instruments, Atotech receive acquisition approval from Royal Court of Jersey - MKS Instruments (MKSI) and Atotech (ATC) announced that the Royal Court of Jersey sanctioned the scheme of arrangement to implement MKS' pending acquisition of Atotech. All material conditions to the closing of the acquisition have now been satisfied and the closing is scheduled for August 17, 2022, when the court order sanctioning the scheme of arrangement will be delivered to the Registrar of Companies for the Bailiwick of Jersey. As previously announced on July 1, 2021, MKS entered into a definitive agreement with Atotech pursuant to which MKS will acquire Atotech for $16.20 in cash and 0.0552 of a share of MKS common stock for each Atotech ordinary share. As previously announced by Atotech, on November 3, 2021, the transaction was approved by Atotech shareholders at a meeting convened pursuant to an order of the Royal Court of Jersey, and a special resolution to implement the transaction was passed by Atotech shareholders at a general meeting.

07:21 EDT MHRA authorizes Moderna's Omicron-Containing bivalent booster in UK - Moderna announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted conditional authorization for the use of the Omicron-containing bivalent COVID-19 booster vaccine, mRNA-1273.214 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 and a vaccine candidate targeting the Omicron variant of concern ."We are delighted with the MHRA's authorization of Spikevax Bivalent Original/Omicron, our next-generation COVID-19 vaccine. This represents the first authorization of an Omicron-containing bivalent vaccine, further highlighting the dedication and leadership of the UK public health authorities in helping to end the COVID-19 pandemic," said Stephane Bancel, Chief Executive Officer of Moderna. "mRNA-1273.214 has consistently shown superior breadth of immune response over mRNA-1273 in clinical trials. This bivalent vaccine has an important role to play in protecting people in the UK from COVID-19 as we enter the winter months." The decision from the MHRA is based on clinical trial data from a phase 2/3 trial, in which mRNA-1273.214 met all primary endpoints, including superior neutralizing antibody response against Omicron when compared to a 50 microgram booster dose of mRNA-1273 in baseline seronegative participants. A booster dose of mRNA-1273.214 increased neutralizing geometric mean titers against Omicron approximately 8-fold above baseline levels. In addition, mRNA-1273.214 elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to the currently authorized booster regardless of prior infection status or age.Moderna is working with The Vaccine Taskforce, UK Health Security Agency, and NHS to make Spikevax Bivalent Original/Omicron available to the UK public. Moderna has completed regulatory submissions for mRNA-1273.214 in Australia, Canada, and the EU and expects further authorization decisions in the coming weeks.

07:19 EDT Gracell sees cash runway into 2024 - As of June 30, 2022, the Company had RMB1,707.3M, or $254.9M, in cash and cash equivalents and short-term investments. In addition, the Company had short-term borrowings and current portion of long-term borrowings of RMB102.3M, or $15.3M, and long-term borrowings of RMB53M, or $7.9M.

07:19 EDT Virios Therapeutics commences enrollment in Long-COVID trial - Virios Therapeutics announced commencement of enrollment in its exploratory Long-COVID trial. This study is supported via an unrestricted investigational grant to the Bateman Horne Center, a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS, FM, post-viral syndromes, and related comorbidities. The trial will assess the safety and effectiveness of antiviral therapy with Virios' second development combination, IMC-2, to treat the symptoms associated with Long-COVID, including fatigue, pain, sleep disruption, anxiety, depression and cognitive function and overall health improvement. IMC-2 is a novel, dual mechanism antiviral therapy combining valacyclovir and celecoxib designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden.

07:16 EDT Nexstar to acquire 75% ownership in The CW Network - Nexstar (NXST) announced that it entered into a definitive agreement to acquire a 75% ownership interest in The CW Network. Warner Bros. Discovery (WBD) and Paramount (PARA), the current co-owners of The CW, will each retain a 12.5% ownership interest in The CW and will continue to produce original, scripted content for the Network. Nexstar, together with its partner stations, is the nation's largest local television broadcasting company and the largest CW affiliate group with 37 CW and CW Plus affiliates, including affiliates in five of the top ten DMAs, accounting for 32% of the Network's national reach. The proposed transaction is expected to create value for Nexstar shareholders by solidifying the company's revenue opportunities as the largest CW affiliate, diversifying its content outside of news, increasing its exposure to the national advertising market, establishing it as a participant in advertising video-on-demand services and improving The CW ratings, revenue, and profitability, by prioritizing programming for the Network's broadcast audience.

07:15 EDT Clene reports topline results for CNM-Au8 in Phase 2 VISIONARY-MS trial - Clene and its wholly owned subsidiary Clene Nanomedicine announced positive topline results from the Phase 2 VISIONARY-MS trial of CNM-Au8, an investigational gold nanocrystal suspension, in participants with stable relapsing remitting multiple sclerosis. VISIONARY-MS was a Phase 2 proof-of-concept, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of CNM-Au8 as adjunctive therapy to currently available disease-modifying therapies versus placebo over 48 weeks in stable RRMS participants with chronic optic neuropathy. As announced in February 2022, the trial was stopped prematurely due to COVID-19 pandemic operational challenges, limiting enrollment to 73 out of the 150 planned participants. Due to the limited enrollment, the threshold for significance was pre-specified at p=0.10 prior to database lock. The primary analysis was conducted in a modified intent to treat population, which censored invalid data. The mITT population excluded data from a single site with LCLA testing execution errors and the timed 25-foot walk data from one subject with a change in mobility assist device. The ITT results were directionally consistent with the mITT results, although the ITT results were not significant. Primary and secondary results from Baseline to Week 48 were: Primary outcome: LCLA letter change in the clinically affected eye. Secondary outcomes: mMSFC mean standardized change; mMSFC average rank score; Time to first repeated clinical improvement to Week 48. Consistent improvements favoring CNM-Au8 were observed across multiple paraclinical biomarkers, including multifocal visual evoked potentials amplitude and latency, optical coherence tomography, and MRI endpoints, including magnetization transfer ratio and diffusion tensor imaging metrics. Placebo treated patients, in contrast, generally worsened as expected across these measures during the 48-week period. These data provide independently assessed quantitative physiological evidence that supports the potential neuroprotective and remyelinating effects of CNM-Au8. The full dataset will be reported at an upcoming scientific congress. CNM-Au8 was well-tolerated, and there were no significant safety findings reported.

07:11 EDT Bitfarms provides expansion plan update - Bitfarms' infrastructure construction contracts are projected to provide 4.2 EH/s as of September 30, 2022 and 6.0 EH/s as of December 31, 2022.The Company already has 1.2 EH/s of miners contracted for 2023 for its Argentinian warehouses.

07:11 EDT Bitfarms defers $39M in capex spending from 4Q22 into 2023 - "By deleveraging our balance sheet and increasing financial flexibility, we are better positioned to execute our growth initiatives to drive market share gains and increased production," said Jeff Lucas, CFO of Bitfarms. "As careful stewards of capital, to better align with our capacity expansion, we amended our miner delivery schedule to match our deployment plan. Thus, we optimized resources, deferring $39 million in capex spending from the fourth quarter of 2022 into 2023." At June 30, 2022, the Company held $46 million in cash and 3,144 BTC valued at approximately $62 million based upon the June 30, 2022 BTC price of approximately $19,800.

07:07 EDT Scynexis expects cash to fund requirements into 1Q24 - Cash and cash equivalents totaled $118.7 million on June 30, 2022, compared to $104.5 million in cash and cash equivalents on December 31, 2021. Based upon its current operating plan, SCYNEXIS believes that its existing cash and cash equivalents, and the anticipated sales of BREXAFEMME, will enable SCYNEXIS to fund its operating requirements into Q1 2024.

07:05 EDT CI Financial reports July AUM $348.5B - CI Financial reported preliminary total assets of $348.5B as at July 31, consisting of asset management assets of $121.5B, Canadian wealth management assets of $77.3B, and U.S. wealth management assets of $149.7B.

07:04 EDT Akouos expects cash to fund operations beyond next eighteen months - Cash, cash equivalents, and marketable securities were $192.9 million as of June 30, 2022, compared to $271.8 million as of June 30, 2021. Akouos expects the cash balance to fund operations beyond the next eighteen months.

07:02 EDT Alaunos Therapeutics expects cash to fund operations into 2Q23 - As of June 30, 2022, Alaunos had approximately $60.0 million in cash and cash equivalents. The Company anticipates its cash runway will be sufficient to fund operations into the second quarter of 2023. Operating cash burn for the second quarter of 2022 was $8.2 million compared to $21.5 million in the second quarter of 2021, a decrease of $13.3 million or 62%.

06:44 EDT ChromaDex's license for NR patent upheld in challenge by Thorne - ChromaDex announced the USPTO's Patent Trial and Appeal Board's decision to reject Thorne Research's attempt to invalidate U.S. Patent No. 8,197,807. ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research from raising these arguments, or any other arguments they could have reasonably raised before the PTAB in the New York District Court lawsuit ChromaDex brought against Thorne Research wherein ChromaDex alleges Thorne Research is infringing the 807 patent. ChromaDex is the exclusive supplier of nicotinamide riboside chloride, Niagen, a novel form of NR. ChromaDex maintains a growing intellectual property portfolio for its proprietary ingredient, Niagen.

06:37 EDT Shoals Technologies names Dominic Bardos as CFO - Shoals Technologies Group (SHLS) announced that Dominic Bardos has been appointed as CFO, effective October 3. Prior to joining Shoals, Bardos served as CFO of Holley (HLLY), a manufacturer and distributor of performance automotive products.

06:35 EDT Fortress Transportation to merge with subsidiary of FTAI Finance Holdco - Fortress Transportation and Infrastructure Investors announced that it had entered into a definitive agreement to merge with a subsidiary of FTAI Finance Holdco Ltd., a Cayman Islands exempted company and subsidiary of the company, with FTAI surviving the merger and becoming a wholly-owned subsidiary of FTAI Finance Holdco Ltd. Following the completion of the merger, FTAI Finance Holdco Ltd. will be named FTAI Aviation Ltd. The transaction is being completed as part of the company's plan to eliminate its partnership tax classification. The surviving entity in the merger, FTAI Aviation, is a corporation. Thus, if the merger is completed, shareholders will no longer receive Form K-1s. In connection with the merger, FTAI's shareholders will receive (i) one ordinary share of FTAI Aviation for each FTAI common share that they own, (ii) one 8.25% Fixed-to-Floating Rate Series A Cumulative Perpetual Redeemable Preferred Share of FTAI Aviation for each 8.25% Fixed-to-Floating Rate Series A Cumulative Perpetual Redeemable Preferred Share of FTAI that they own, (iii) one 8.00% Fixed-to-Floating Rate Series B Cumulative Perpetual Redeemable Preferred Share of FTAI Aviation for each 8.00% Fixed-to-Floating Rate Series B Cumulative Perpetual Redeemable Preferred Share of FTAI that they own and (iv) one 8.25% Fixed-Rate Reset Series C Cumulative Perpetual Redeemable Preferred Share of FTAI Aviation for each 8.25% Fixed-Rate Reset Series C Cumulative Perpetual Redeemable Preferred Share of FTAI that they own. The completion of the Merger is subject to the satisfaction or waiver of certain mutual closing conditions, including, among others, (i) the affirmative vote of holders of a majority of the issued and outstanding FTAI common shares entitled to vote on such matter having approved adoption of the Merger Agreement and (ii) the effectiveness of the final registration statement on Form S-4 to be filed by FTAI Aviation registering the FTAI Aviation ordinary shares and the FTAI Aviation preferred shares to be issued in connection with the Merger with the SEC. FTAI Aviation filed a preliminary registration statement on Form S-4 with the SEC on August 12.

06:03 EDT Regis successfully amends credit facility - Regis announced that it successfully amended its credit facility and extended the maturity date from March 23, 2023 to August 31, 2025. Under the amendment, the revolving credit facility was converted to a $180M term loan and $55M revolving credit facility with the minimum liquidity covenant reduced to $10M from $75M. The amended credit agreement includes typical provisions and financial covenants, including minimum EBITDA, leverage and fixed-charge coverage ratio covenants, the latter two of which are not tested until December 31, 2023. "We are pleased with the outcome of our debt refinancing efforts. The terms of the amended credit agreement provide us with adequate runway and liquidity to invest in the strategic priorities that we believe will lead us to improved revenue and profitability," said Kersten Zupfer, Regis Corporation's Executive Vice President and CFO.

05:26 EDT Opthea receives funding for OPT-302 trials, pre-commercialization activities - Opthea (OPT) announced a non-dilutive financing transaction for up to $170M from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration, or wet AMD. Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle (CG) and its life sciences franchise, Abingworth. Under the terms of the agreement, the funds managed by Carlyle and Abingworth, in collaboration with Launch Tx, will commit $120M in three installments at fixed time points and retain an option to commit another $50M, representing total funding of up to $170M for Opthea. If OPT-302 is approved in a major market, Opthea will make a milestone payment after regulatory approval and then six subsequent annual fixed success payments and variable success payments of 7% of net sales, with cumulative payments capped at four times the amount funded to Opthea. Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time.

05:17 EDT Altera Infrastructure executes RSA, enters Chapter 11 bankruptcy process - Altera Infrastructure and certain of its subsidiaries announced that it has executed a restructuring support agreement, or RSA, with approximately 71% of Altera's funded debt obligations, which includes Brookfield and a super-majority of its bank lenders. All in, the RSA has been signed, or agreed to in principle by, holders of 80% of its funded debt obligations, which includes approximately 91% of its bank lenders pending certain creditors' internal credit approval processes. The terms of the RSA establish the framework for a consensual and comprehensive financial restructuring that will deleverage Altera's balance sheet and position Altera for long-term growth and success. To implement the balance-sheet restructuring, Altera has commenced a Chapter 11 process in the United States Bankruptcy Court for the Southern District of Texas. The RSA contemplates, among other things, addressing more than $1B of secured and unsecured holding company debt, $400M of preferred equity, and $550M of secured asset-level bank debt, a reprofiling of Altera's bank loan facilities to better align cash flow with debt service obligations, and the continued support of Altera's equity sponsor, Brookfield. In addition, Altera has obtained a commitment from Brookfield for a $50M debtor in possession financing to help fund Altera's restructuring process and ensure ordinary course operations remain unimpaired during the Chapter 11 process. In conjunction with the petitions Altera has filed a series of motions, which, once approved by the court, will enable the company to operate its business in the ordinary course without interruption. These motions will also allow Altera to continue to honor obligations to its employees, customers, and suppliers on previously agreed upon schedules and terms on an uninterrupted basis. Ingvild Sther, CEO of Altera Infrastructure, commented: "We enter into this phase of our balance-sheet restructuring with the support of the majority of Altera's secured lenders and equity sponsor Brookfield. We are confident that this Chapter 11 process will result in a comprehensive recapitalization transaction that will not only stabilize liquidity, but also deleverage our balance sheet and better position Altera for future growth."

05:13 EDT Novartis announces CANOPY-A trial did not meet primary endpoint - Novartis announced that the Phase 3 CANOPY-A study evaluating adjuvant treatment with canakinumab, an inhibitor of interleukin-1beta, in adult patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer, or NSCLC, did not meet its primary endpoint of disease-free survival versus placebo. No unexpected safety signals were observed. Findings from the trial will be presented at an upcoming medical meeting. In the trial, 1,382 patients were randomized 1:1 to canakinumab, 200 mg subcutaneously every three weeks, or matching placebo for up to one year. Patients completed standard-of-care adjuvant cisplatin-based chemotherapy and radiation therapy, if applicable, prior to randomization. "We made an investment in the CANOPY program based on signals of reduced lung cancer incidence and mortality observed in the CANTOS study. These positive signals supported the study of canakinumab as adjuvant treatment for early lung cancer. While we are disappointed CANOPY-A did not show the benefit we hoped for, every trial generates scientific evidence that supports future research and development, and we look forward to continuing to pursue new therapeutic options for people living with lung cancer, whose needs remain urgent and significant. We thank the patients and clinical investigators whose time and commitment made this research possible," said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development, Novartis.